These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 25107680)

  • 41. Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial.
    Tsang SH; Sampson JN; Schussler J; Porras C; Wagner S; Boland J; Cortes B; Lowy DR; Schiller JT; Schiffman M; Kemp TJ; Rodriguez AC; Quint W; Gail MH; Pinto LA; Gonzalez P; Hildesheim A; Kreimer AR; Herrero R;
    J Natl Cancer Inst; 2020 Oct; 112(10):1030-1037. PubMed ID: 32091596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
    Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
    Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Change in Human Papillomavirus Prevalence Among U.S. Women Aged 18-59 Years, 2009-2014.
    Berenson AB; Hirth JM; Chang M
    Obstet Gynecol; 2017 Oct; 130(4):693-701. PubMed ID: 28885413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction.
    Kahn JA; Brown DR; Ding L; Widdice LE; Shew ML; Glynn S; Bernstein DI
    Pediatrics; 2012 Aug; 130(2):e249-56. PubMed ID: 22778297
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human papillomavirus prevalence and vaccine effectiveness in young women in Germany, 2017/2018: results from a nationwide study.
    Loenenbach A; Schönfeld V; Takla A; Wiese-Posselt M; Marquis A; Thies S; Sand M; Kaufmann AM; Wichmann O; Harder T
    Front Public Health; 2023; 11():1204101. PubMed ID: 37719724
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003-2018.
    Rosenblum HG; Lewis RM; Gargano JW; Querec TD; Unger ER; Markowitz LE
    MMWR Morb Mortal Wkly Rep; 2021 Mar; 70(12):415-420. PubMed ID: 33764964
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectiveness of Human Papillomavirus Vaccination on Prevalence of Vaccine Genotypes in Young Sexually Active Women in France.
    Heard I; Tondeur L; Arowas L; Demazoin M; Falguières M; Parent Du Chatelet I;
    J Infect Dis; 2017 Mar; 215(5):757-763. PubMed ID: 28011911
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of bivalent and quadrivalent human papillomavirus vaccination in Luxembourg.
    Latsuzbaia A; Arbyn M; Tapp J; Fischer M; Weyers S; Pesch P; Mossong J
    Cancer Epidemiol; 2019 Dec; 63():101593. PubMed ID: 31499377
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction.
    Widdice LE; Bernstein DI; Franco EL; Ding L; Brown DR; Ermel AC; Higgins L; Kahn JA
    Vaccine; 2019 Oct; 37(45):6832-6841. PubMed ID: 31582269
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
    Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
    Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study.
    Woestenberg PJ; Bogaards JA; King AJ; Leussink S; van der Sande MA; Hoebe CJ; van Benthem BH;
    Int J Cancer; 2019 Jun; 144(11):2718-2727. PubMed ID: 30426502
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.
    Brisson M; Bénard É; Drolet M; Bogaards JA; Baussano I; Vänskä S; Jit M; Boily MC; Smith MA; Berkhof J; Canfell K; Chesson HW; Burger EA; Choi YH; De Blasio BF; De Vlas SJ; Guzzetta G; Hontelez JAC; Horn J; Jepsen MR; Kim JJ; Lazzarato F; Matthijsse SM; Mikolajczyk R; Pavelyev A; Pillsbury M; Shafer LA; Tully SP; Turner HC; Usher C; Walsh C
    Lancet Public Health; 2016 Nov; 1(1):e8-e17. PubMed ID: 29253379
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness of a universal vaccination program with an HPV quadrivalent vaccine in young Brazilian women.
    Wendland EM; Kops NL; Bessel M; Comerlato J; Maranhão AGK; Souza FMA; Villa LL; Pereira GFM
    Vaccine; 2021 Mar; 39(13):1840-1845. PubMed ID: 33674171
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quadrivalent human papillomavirus vaccination successfully reduces the prevalence of vaccine-targeted genotypes in a young, vaccine-eligible-age sample of Australian females.
    Subasinghe AK; Wark JD; Phillips S; Cornall A; Brotherton JML; Garland SM
    Sex Health; 2020 Dec; 17(6):510-516. PubMed ID: 33341122
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevalence of human papillomavirus genotypes in high-grade cervical precancer and invasive cervical cancer from cancer registries before and after vaccine introduction in the United States.
    Mix JM; Saraiya M; Thompson TD; Querec TD; Greek A; Tucker TC; Peters ES; Lynch CF; Hernandez BY; Copeland G; Goodman MT; Unger ER
    Cancer; 2021 Oct; 127(19):3614-3621. PubMed ID: 34289090
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.
    Donovan B; Franklin N; Guy R; Grulich AE; Regan DG; Ali H; Wand H; Fairley CK
    Lancet Infect Dis; 2011 Jan; 11(1):39-44. PubMed ID: 21067976
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of human papillomavirus vaccination on racial/ethnic disparities in vaccine-type human papillomavirus prevalence among 14-26 year old females in the U.S.
    Hirth J; McGrath CJ; Kuo YF; Rupp RE; Starkey JM; Berenson AB
    Vaccine; 2018 Nov; 36(50):7682-7688. PubMed ID: 30377066
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differences between vaccinated and unvaccinated women explain increase in non-vaccine-type human papillomavirus in unvaccinated women after vaccine introduction.
    Ding L; Widdice LE; Kahn JA
    Vaccine; 2017 Dec; 35(52):7217-7221. PubMed ID: 29169890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.